← All trials
NCT05822609
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Apr 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
- Providence Health & ServicesCollaborator
- Providence Health & ServicesOverall official - principal investigator
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of Colorado, DenverCollaborator
- University of ColoradoOverall official - principal investigator
- Juvenile Diabetes Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.